Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astrazeneca Plc Ord (OP: AZNCF ) 154.46 +1.16 (+0.76%) Streaming Delayed Price Updated: 1:57 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Astrazeneca Plc Ord < Previous 1 2 3 4 5 6 7 8 Next > Why Are AstraZeneca Shares Trading Higher Today February 15, 2022 Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease... Via Benzinga AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21 February 10, 2022 AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0 Via Benzinga AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences February 03, 2022 AstraZeneca plc (NASDAQ: AZN) has granted Via Benzinga Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial January 25, 2022 Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is... Via Benzinga Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows January 24, 2022 A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ... Via Benzinga Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder January 24, 2022 The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... Via Benzinga Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg January 21, 2022 According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine... Via Benzinga AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer January 19, 2022 A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable... Via Benzinga AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US January 13, 2022 AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-... Via Benzinga AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use January 13, 2022 AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third... Via Benzinga Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies January 13, 2022 Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron... Via Benzinga Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins January 13, 2022 AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines... Via Benzinga Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact January 03, 2022 Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small... Via Benzinga Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron December 23, 2021 A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab... Via Benzinga AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma December 20, 2021 The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult... Via Benzinga Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study December 17, 2021 COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no... Via Benzinga AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant December 16, 2021 New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against... Via Benzinga Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back December 15, 2021 Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... Via Benzinga Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy December 14, 2021 Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc (NASDAQ: AZN) on manufacturing biopharmaceuticals. According to Samsung, the production... Via Benzinga AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK December 10, 2021 On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor... Via Benzinga Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity December 09, 2021 Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an... Via Benzinga AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised December 09, 2021 The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a... Via Benzinga Exposures COVID-19 Product Safety Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response December 07, 2021 A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or ... Via Benzinga Exposures COVID-19 Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder December 07, 2021 Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... Via Benzinga Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population December 03, 2021 Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of... Via Benzinga Exposures COVID-19 AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report December 03, 2021 AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... Via Benzinga Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots December 02, 2021 Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to... Via Benzinga Exposures COVID-19 AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting November 30, 2021 The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer.... Via Benzinga Exposures Product Safety AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance November 12, 2021 AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new... Via Benzinga Exposures COVID-19 AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report November 10, 2021 AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and... Via Benzinga Exposures COVID-19 < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
